

## RESEARCH ARTICLE

# Evaluation of Invasive and Noninvasive Methods for the Diagnosis of Helicobacter Pylori Infection

Yasemin Cosgun<sup>1\*</sup>, Abdullah Yildirim<sup>2</sup>, Mihriban Yucel<sup>3</sup>, Ayse Esra Karakoc<sup>3</sup>, Gokhan Koca<sup>4</sup>, Alpaslan Gonultas<sup>5</sup>, Gul Gursoy<sup>6</sup>, Huseyin Ustun<sup>5</sup>, Meliha Korkmaz<sup>4</sup>

### Abstract

**Objective:** The present study was conducted to evaluate invasive and noninvasive diagnostic methods for detection of *Helicobacter pylori* (*H. pylori*) in patients admitted with dyspeptic complaints and to compare sensitivities and specificities. **Method:** Sets of four gastric biopsy specimens were obtained from a total of 126 patients included in the study. The presence of *H. pylori* was determined by invasive tests including culture, rapid urease test, polymerase chain reaction (PCR) and histopathology. Among noninvasive tests, urea breath test, serological tests and enzyme-linked immunosorbent assay (ELISA) were performed. **Results:** *H. pylori* was isolated in 79 (62.7%) gastric biopsy cultures, whereas positivity was concluded for 105 (83.3%) patients by rapid urease test, for 106 (84.1%) by PCR, for 110 (87.3%) by histopathology, for 119 (94.4%) by urea breath test, and for 107 (84.9%) by ELISA. In the present study, the culture findings and histopathological examination findings were accepted as gold standard. According to the gold standard, urea breath test had the highest sensitivity (96.5%) and the lowest specificity (30%), whereas culture and histopathology had the highest specificities (100%). **Conclusion:** The use of PCR invasively with gastric biopsy samples yielded parallel results with the gold standard. PCR can be recommended for routine use in the diagnosis of *H. pylori*.

**Keywords:** *Helicobacter pylori*, diagnostic tests, polymerase chain reaction

*Asian Pac J Cancer Prev*, 17 (12), 5265-5272

### Introduction

*H. pylori*, which colonizes the gastrointestinal tract of nearly half of the world's population, is a spiral-shaped, gram-negative microorganism causing local inflammation in the stomach and duodenum and inducing humoral immune response systemically (Ozden, 2006; Sanders et al., 2006). Recently, *H. pylori* is considered a causative agent in the development of non-ulcer dyspepsia, peptic and gastric ulcers, chronic gastritis, gastric carcinoma, and mucosa associated lymphoid tissue (MALT)-type lymphoma. *H. pylori* was classified as a class I human carcinogen by World Health Organization in 1994 (Asaka, 2002; WHO, 1997). In February 1994, National Institutes of Health proposed that patients infected with *H. pylori* should be absolutely treated with antibiotics (Thamer et al., 1998).

Numerous invasive and noninvasive methods have been developed for the diagnosis of *H. pylori* and many of them have been implemented in practice. Invasive methods include direct microscopic examination, culture, rapid urease test, histopathological examination, and

molecular evaluation of biopsy samples; noninvasive methods include urea breath test, serological tests, fecal antigen test, measurement of <sup>13</sup>C in blood and stool samples, molecular evaluation of samples other than biopsy samples.

There is no single test serving as a gold standard for the diagnosis; however, culture and histopathological analysis of biopsy samples have been accepted as the gold standard methods. A novel noninvasive, cheap, easily applicable, rapid method with high sensitivity and specificity has not been established yet (Dunn et al., 1997; Li et al., 1996; Laheij et al., 2000). Invasive and noninvasive methods have both advantages and disadvantages. The choice of the diagnostic method depends on complaints and age of the patients, as well as physical examination findings, previous history of endoscopy, family history of gastric cancer, whether the patient had received treatment or not, *H. pylori* seroprevalence in the population, and preference of the patients and physicians. Generally accepted approach is the use of two or three biopsy-based tests as a gold standard (Laheij et al., 2000; Ogata et al., 2001; Vinette et al., 2004).

<sup>1</sup>Public Health Institute of Turkey Microbiology Reference Laboratories Department, <sup>3</sup>Department of Medical Microbiology, <sup>4</sup>Department of Nuclear Medicine, <sup>5</sup>Department of Medical Pathology, Ankara Training and Research Hospital, <sup>6</sup>Departement of Internal Medicine, Ankara Education and Research Hospital, Ankara, <sup>2</sup>Gaziantep University, Faculty of Medicine, Turkey. \*For Correspondence: yasemincosgun2006@yahoo.com.tr

In the present study, invasive methods such as rapid urease test, culture, histopathology, and polymerase chain reaction (PCR) and noninvasive methods such as urea breath test and serological tests were used to diagnose *H. pylori* in endoscopic biopsy samples obtained from patients with dyspeptic complaints; and it was aimed to compare the sensitivity and specificity of these invasive and noninvasive methods in the diagnosis.

## Materials and Methods

This study was carried out in 4 months at the Ankara Training and Research Hospital Microbiology Laboratory. One-hundred twenty-six patients, who were admitted to Outpatient Clinic of Internal Diseases with dyspeptic complaints and in whom endoscopy was indicated, were included in the study. The study group comprised patients not using antibiotics in the last one month, those not using proton-pump inhibitors (PPIs) for the last 14 days, and those not using H2 receptor antagonist or antacids for the last 24 hours.

### Samples

Totally four biopsy specimens (two antral and two corpus biopsy specimens) were obtained from the patients in whom esophagogastroduodenoscopy was performed following at least eight hours of fasting. The first biopsy sample was placed in a glass tube containing 1 mL sterile saline (0.9% NaCl); the second biopsy sample was placed in a glass tube containing 1 mL 2% Christensen's urea medium for culture; the third biopsy sample was placed in a 2 mL eppendorf tube containing 1 mL nuclease-free distilled water for PCR. Following 8 hours of fasting, 7 mL blood samples of the patients were drawn into serum separator tubes with gel for serological tests. Breath samples were collected from patients for urea breath test.

### Invasive Methods

#### Rapid urease test

The samples, which were placed in tubes containing rapid urease medium and immediately transferred to laboratory, were examined at endoscopy unit. The color of the medium changed from yellow to dark pink and fuchsia color was accepted as a positive result. If no change was observed in the color of the medium, samples were incubated at 35°C for 24 hours. The samples were re-evaluated at the 2nd and 24th hours in terms of positivity.

### Culture

Brain Heart Infusion (BHI) agar (Oxoid, England) containing 10 mg/L vancomycin, 5 mg/L cefsulodin, 5 mg/L amphotericin-B, 5 mg/L trimethoprim (*H. pylori* selective medium, Oxoid, England) and 10% defibrinated horse blood was used. The biopsy samples, which were transferred to laboratory in glass tubes containing 1 mL sterile saline (0.9% NaCl), were cut into pieces using scalpel in sterile glass petri dishes. The samples were homogenized and then inoculated to BHI agar. The plates were placed in a 3.5 L jar with CampyGen (Oxoid, England) and the jar was closed within one minute. The

plates were incubated for 7 days at 35°C. At the end of the incubation period, the grey, translucent colonies 1-2 mm in diameter with weak beta-hemolysis were considered suspicious for *H. pylori* and examined by conventional methods. Pure growth was obtained, since selective medium was used. The bacteria were identified by Gram staining and by performing urease, oxidase and catalase tests. Curved, S-shaped or seagull-wing-shaped appearance in Gram staining and positive urease, oxidase and catalase tests were defined as *H. pylori* positivity.

### Polymerase Chain Reaction for the detection of *H. Pylori* in biopsy samples

In-house nested PCR assay was used to detect *H. pylori* DNA. DNA extraction was performed by the phenol-chloroform method. The primers were 5'-AACGGTCCTAAGGTAGCGAA-3' and 5'-ACACTCAACTTGCGATTCC-3' for the first-step amplification 408 base pairs (bp) product of *H. pylori* 23S rRNA, and the primers were 5'-ATGAATGGCGTAACGAGAT-3' and 5'-GTGCTAAGTTGTAGTAAAGGT-3' for the second-step amplification 126 bp product of *H. pylori* 23S rRNA.

PCR reaction mixture was prepared in 5 µL eppendorf tubes by mixing 5 µL 10X PCR buffer, 0.5 µL dNTPs (10 mM), 0.2 µL Taq polymerase (5 U/µL), 2 µL magnesium (25 mM), primers 0.5 µL for each (100 pmol/µL), and 36.3 µL nuclease-free water. Finally, 5 µL DNA samples were added to the PCR reaction mixture, and the tubes were placed in a thermal cycler device (Techne, England) for first-step amplification. *H. pylori* NCTC 11637 reference strain was used as positive control and nuclease-free water was used as negative control.

The amplification conditions for the first-step amplification product were: one cycle of initial denaturation at 94°C for 5 min, 30 cycles of denaturation at 94°C for 30 sec, annealing at 55°C for 45 sec, one cycle of elongation at 72°C for 60 sec, and one cycle of final elongation at 72°C for 5 min. A 5 µL DNA sample from the obtained amplification product was added to the PCR mixture (45 µL) in 0.5 mL eppendorf tubes and the tubes were placed in thermal cycler device (Techne, England). The amplification conditions for the second-step amplification product were: one cycle of initial denaturation at 94°C for 3 min, 30 cycles of denaturation at 94°C for 20 sec, annealing at 55°C for 35 sec, elongation at 72°C for 45 sec, and one cycle of final elongation at 72°C for 5 min.

Amplified PCR products, positive and negative control samples and DNA marker (Gene Ruler 100bp DNA ladder, MBI Fermentas, Lithuania) were transferred to wells and separated by agarose gel electrophoresis; direct current was applied at a voltage of 150 V for 35-40 min. Results were evaluated in terms of the presence of first-step amplification 408 bp product and second-step amplification 126 bp product with a UV transilluminator (Vilber Lourmat, France).

### Histopathological Examination

6-µm in-thick sections were obtained from the specimens that were transferred to the pathology laboratory in 10% neutral formalin solution. The sections

were then stained with routine hematoxylin and eosin (H&E) stain and were evaluated under a light microscope. The samples were evaluated for *H. pylori* colonization and gastric pathologies; the intensity of *H. pylori* was classified according to the Sydney classification in four different grades.

#### Noninvasive Methods

##### Serological Evaluation

Serum antibody levels were measured quantitatively with a micro enzyme-linked immunosorbent assay (ELISA) device (Alisei, Italy) using a commercial ELISA kit (Radim, Italy) to detect anti-*H. pylori* IgG and anti CagA IgG antibodies.

##### Urea Breath Test

By paying attention that patients did not use antibiotics and bismuth within the last one month, PPIs within the last 14 days, and antacids and H<sub>2</sub> receptors within the last 24 hours, a capsule (HeliCap) containing 1  $\mu$ Ci 14C-labeled urea and citric acid was administered perorally with 50 mL water to the patients following at least six hours of fasting. Ten minutes after administration of the capsule, the patients exhaled into breath cartridge (Heliprobe Breathcard, Sweden) for five minutes until the color changed from orange to yellow. The cartridge was placed in an analyzer (Heliprobe-analyzer, Sweden) and activity count was performed for 250 sec. The labeled CO<sub>2</sub> collected in the cartridge was expressed as counts per min (cpm). The result was calculated automatically by the device and graded as grades 0, 1, and 2.

## Results

In the present study, the culture findings and histopathological examination findings were accepted as gold standard. The detection of *H. pylori* at least one of the two tests was accepted as *H. pylori* positivity. Negative results in both culture and histopathology were accepted as *H. pylori* negativity.

The age range of the 126 patients (85 females (64.4%) and 41 males (32.6%)) was 14 to 74 years. The mean ages of female and male patients were 37.1 $\pm$ 13.1 and 38.8 $\pm$ 13.1 years, respectively (Figure 1).

No statistically significant difference was determined between male and female patients in terms of age ( $p>0.05$ ). Of the male patients, 38 (92.6%) were *H. pylori* positive; of the female patients, 78 (91.7%) were *H. pylori* positive.




Figure 1. *H. pylori*-Positive Status by Gender




Figure 2. *H. pylori*-Positive Status of the Patients According to Age Groups

There was no significant difference between female and male patients in terms of *H. pylori* positivity ( $p>0.05$ ).

Patients with *H. pylori*-positive status is shown in Figure 2 according to the age group (Figure 2).

The most frequent endoscopic diagnosis was antral gastritis (Table 1)

According to the culture and/or histopathological methods that were accepted as gold standard, *H. pylori* positivity was determined in 116 (92%) patients and *H. pylori* negativity was determined in 10 (8%) patients. *H. pylori* positivity was determined in 73 patients both in cultural and histopathological examinations, whereas *H. pylori* negativity was determined in 10 patients in both examinations. *H. Pylori* positivity was determined in 124 (98.4%) patients in at least one of the six tests performed on 126 patients. Of the patients included in the study, positive results were obtained in 56 (44.4%) patients in all tests and negative results were obtained in 2 (1.58%) patients in all tests.

#### Culture

Of 126 patients, *H. pylori* was isolated from gastric biopsy cultures of 79 (62.7%) patients; however, *H. pylori* could not be isolated in 47 (37.3%) patients. *H. pylori* was detected by histopathology in 37 of 47 patients in whom culture results for *H. pylori* was negative; these results were interpreted as false negative results for culture. A significant difference was found between the culture method and the gold standard in terms of the rate of *H. pylori* positivity ( $p=0.0001$ ).

#### Histopathological Examination

While *H. pylori* positivity was determined in 110

Table 1. Distribution of the Study Patients According to Endoscopic Diagnosis

Endoscopic diagnosis	n (%)
Pangastritis	11 (8.7)
Antral gastritis	60 (47.6)
Antral gastritis + duodenitis	16 (12.7)
Antral gastritis + esophagitis	17 (13.5)
Esophagitis	2 (1.6)
Peptic ulcer	17 (13.5)
Normal	3 (2.4)
Total	126 (100)

Table 2. The Sensitivity, Specificity, Positive and Negative Predictive Values of the Tests Performed in the Study According to Gold Standard

Tests	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
Culture	68.1	100	100	21.2
Rapid urease test	87.9	70	97.1	33.3
PCR	88.7	70	97.1	35
Histopathology	94.8	100	100	62.5
Urea breath test	96.5	30	94.1	42.8
ELISA	86.2	40	94.3	20

(87.3%) patients by histopathological examination of biopsy samples, the presence of *H. pylori* was not determined in 16 (16.6%) patients. *H. pylori* positivity was determined by culture in 6 of 16 patients in whom *H. pylori* negativity was determined by histopathology; these results were interpreted as false negative results for histopathological examination. No significant difference was found between the histopathological examination and the gold standard in terms of the rate of *H. pylori* positivity ( $p=0.3$ ).

#### Rapid Urease Test

*H. pylori* positivity was determined in biopsy samples of 105 (83.3%) patients and *H. pylori* negativity was determined in biopsy samples of 21 (16.7%) patients by rapid urease test. No significant difference was found between the rapid urease test and the gold standard in terms of the rate of *H. pylori* positivity ( $p=0.054$ ).

#### Urea Breath Test

Of 126 patients, *H. pylori* positivity was determined in 119 (94.4%) patients, whereas *H. pylori* negativity was determined in 7 (5.6%) patients by urea breath test. No significant difference was found between the urea breath test and the gold standard in terms of the rate of *H. pylori* positivity ( $p>0.62$ ).

#### Polymerase Chain Reaction (PCR)

*H. pylori* positivity was determined in 106 (84.1%) patients and *H. pylori* negativity was determined in 20 (15.9%) patients by PCR of biopsy samples. No significant difference was found between the PCR method and the gold standard in terms of the rate of *H. pylori* positivity ( $p=0.07$ ).

#### Enzyme-Linked Immunosorbent Assay (ELISA)

*H. pylori* positivity was determined in 107 (84.9%) patients and *H. pylori* negativity was determined in 19 (15.1%) patients by ELISA in serum samples of 126 patients. No significant difference was found between the ELISA and the gold standard in terms of the rate of *H. pylori* positivity ( $p=0.11$ ). In addition, anti-*H. pylori* CagA IgG antibodies were measured in the patients' serums using ELISA method. Of the 107 patients in whom anti-*H. pylori* IgG was positive, 75 (70%) patients were positive for anti-*H. pylori* CagA IgG (Table 2).

## Discussion

The excitement beginning with isolation of *H. pylori* from gastric biopsies by Warren and Marshall in 1982

has increasingly continued after the important role of this bacterium in the etiology of gastric cancer has been established; thus, the interest in *H. pylori* has increased (Ozden, 2006). The association of gastric cancer, one the most frequent causes of death worldwide, with a treatable etiological factor have led to a profound impact on the researchers in the field of gastro-oncology and brought the 2005 Nobel Prize to the researchers who isolated the bacteria and proved its association with gastric diseases (Ozden, 2006; Marshall and Warren, 1984). *H. pylori* infection is acquired in early childhood, and colonization occurs in the stomach. The earlier the infection starts, the risk of complications associated with *H. pylori* increases (Asaka, 2002; Dunn et al., 1997; Konturek, 2003; Brown, 2000; Yang et al., 2006).

Accurate and suitable diagnosis and treatment of this infection affecting human health to such a serious extent, deteriorating quality of life of all age groups, and even causing death is of importance. For this purpose, many diagnostic methods have been developed and some of them have been implemented in practice. Each method has both advantages and disadvantages due to different reasons such as discomfort to patients, side effects, costs, duration of the tests, workforce, and requirements of special conditions.

In the recent consensus reports, the use of noninvasive methods, particularly urea breath test and fecal antigen tests, have been suggested for the detection and treatment of *H. pylori* in patients under the age of 45 years with dyspeptic complaints and without alarm symptoms in the populations with high seroprevalence rates, like in Turkey. The use of invasive methods requiring endoscopic biopsy has been suggested in the presence of alarm symptoms (namely epigastric pain, severe vomiting, unexplained weight loss, unexplained anemia), in subjects over the age of 45 years, in case of impossibility to eradicate the bacteria despite treatment, and in the presence of family history of gastric cancer (Ozden, 2006; Mitchell and Megraud, 2002; Ellidokuz et al., 2003). Histopathology among invasive methods and urea breath test and ELISA among noninvasive methods are the most frequently used methods in the world and in Turkey (Ozden, 2006; Dunn et al., 1997; Malaty et al., 2002; Ozden et al., 2004; Weiss et al., 1994).

In the studies evaluating diagnostic methods for *H. pylori*, the use of biopsy-based invasive methods has been accepted as gold standard. Gold standard is determined by the combined use invasive methods, particularly culture and histopathology, in some studies, whereas



gold standard is determined by the use of rapid urease test together with these methods in some other studies (Laheij et al., 2000; Ogata et al., 2001; Vinette et al., 2004; Weiss et al., 1994; Uyanik et al., 2007; Somily et al., 2015; Wong et al., 2014). When the gold standard tests in our study were taken into consideration, *H. pylori* positivity was determined in 116 (92%) of the patients, whereas *H. pylori* negativity was determined in 10 (8%) patients. In addition, *H. pylori* positivity was determined in 124 (98.4%) of 126 patients in at least one of the six tests performed. In the study by Uyanik et al., *H. pylori* positivity was determined to be 86% by at least one test in patients with upper gastrointestinal complaints (Uyanik et al., 2007). In addition to high seroprevalence rates of *H. pylori* in the population, the higher rate of *H. pylori* positivity determined in our study could be attributed to the fact that our patient population comprised those with severe upper gastrointestinal symptoms in whom endoscopy was indicated.

Although the culture method is accepted as a “gold standard” for the diagnosis, it is difficult to use culture method alone as a routine diagnostic method. As the sensitivity of culture method for the detection of *H. pylori* is low, *H. pylori* positivity can be detected accurately in case of growth; however, absence of growth does not indicate *H. pylori* negativity. The use of culture together with other tests in order to monitor antimicrobial resistance patterns is beneficial in terms of directing treatment particularly in populations in which drug resistance is high (Baglan et al., 2005; Matsumura et al., 2001). In the present study, the culture method had the lowest sensitivity with a rate of 68.1%. Of 126 patients, growth was observed in culture in 79 patients, whereas no growth was observed in culture in 47 patients. Of the 47 culture-negative patients, *H. pylori* positivity was determined by histopathology in 37 patients, and these were evaluated as false negative results for culture. Of the culture-negative histopathology-positive 37 patients, the other tests except for histopathology were positive in 17 patients, whereas rapid urease test was negative in 9 patients in whom culture results were also negative.

In addition to inaccurate sampling due to patchy localization pattern which is observed in all invasive tests, the false negative results observed in the *H. pylori* culture could be attributed to oxygen sensitivity of the bacteria, the need of bacteria for special transport and growth conditions, and the transformation of bacteria into coccoid forms in in-vitro conditions. Because of all these reasons, the sensitivity of culture method to detect *H. pylori* ranges from 20% to 100% in the studies performed (Laheij et al., 2000; Ogata et al., 2001; Weiss et al., 1994; Kaya et al., 2007). As the bacteria transforms to coccoid forms in in-vitro conditions, growth in culture is not observed, although enzyme activities and histopathological findings are positive. In their study, She et al., induced the transformation of *H. pylori* strains into coccoid forms by the use of antibiotics and evaluated the virulence factors of *H. pylori* strains; they observed that despite the absence of growth in culture, urease activities of the strains remained but vacuolating effect disappeared (She et al., 2001).

Since resistance is encountered in one of every four patients diagnosed with noninvasive methods and treated in the populations in which the rate of clarithromycin resistance is over 25%, like in Turkish population, sensitivity tests become important. When endoscopy is performed on the patients who are treated after the diagnostic test but in whom symptoms do not regress, obtaining biopsy specimens for sensitivity and culture tests in addition to histopathological examination appears to be the best suitable approach (Asaka, 2002; Thamer et al., 1997; Dunn et al., 1997; Brown, 2000; Baglan et al., 2005; Baglan et al., 2006). Since histopathological examination is based on direct observation of bacteria in the samples by means of stains, it is a method with a high sensitivity and specificity rates (Wong et al., 2014; Dunn et al., 1997; Weiss et al., 1994). In our study, histopathological examination was evaluated as a gold standard together with culture. It was found to be the test with the second highest sensitivity after urea breath test. The sensitivity and specificity of histopathological examination were calculated to be 94.8% and 100%, respectively. In the study performed by Vinette et al. on pediatric patients, the sensitivity and specificity of histopathological examination was reported to be 100% and 97.8%, respectively (Vinette et al., 2004). In their study Kobayashi et al. reported the sensitivity to be 99% and specificity to be 94% for histopathological evaluation (Kobayashi, 2002). False negative results for the histopathological examination were considered to depend on patchy localization pattern of the bacteria in the gastric epithelium.

As rapid urease test is based on biopsy, it has been accepted as a gold standard test together with culture or histopathology in many studies (Laheij et al., 2000; Vinette et al., 2004; Kaya et al., 2007). In addition to being cost-effective, rapid urease test has some advantages such as not requiring special conditions and providing results in a short period of time (within one hour) (Dunn et al., 1997). In the present study, *H. pylori* positivity was determined in 105 patients by rapid urease test and *H. pylori* negativity was determined in 21 patients. The sensitivity, specificity and PPV of the rapid urease test were found to be 87.9%, 70% and 97.1%, respectively. No significant difference was determined between the rapid urease test and gold standard in terms of the rates of *H. pylori* positivity ( $p=0.054$ ). Two of the three false-positive results were also determined to be positive by urea breath test. Since both tests are based on urease enzyme, it was considered that this result could be due to the contamination by other bacteria producing urease. In their study, Brandi et al., (2006) performed urea breath test, rapid urease test, culture and histopathological examination on biopsy samples and determined that urease-positive bacteria other than *H. pylori* led to false positive results for rapid urease and urea breath tests.

Polymerase chain reaction technique can be used for the determination of diagnosis and antibiotic sensitivity to detect bacteria and resistant genes. In addition, it can be used to detect genetic differences among *H. pylori* species in epidemiological studies. In the present study, nested PCR method used for detecting a target sequence located in the 23S rRNA showed a good correlation

with gold standard methods. Of the 126 samples, *H. pylori* positivity was determined in 106 and *H. pylori* negativity was determined in 20. Three false positive and 13 false negative results were obtained. The fact that PCR is a method prone to contamination, and the possibility of determining *H. pylori* positivity due to bacteria colonization in oral region and dental plaques and amplification of DNA from dead bacteria affect the reliability of PCR technique.

Three false positive results determined in our study were lower than the rates of false positive results found in the studies performed using PCR technique. The target gene region and the PCR technique used affect the reliability of the test in the studies utilizing PCR technique. In the PCR studies, in which a target sequence located in the 16S rRNA has been selected, the rates of false positive results have been found to be high (Trebesius et al., 2000; Bulut et al., 2006). In their study, Lu et al. compared five separate primer pairs and accepted culture as the gold standard method. They reported the sensitivity of 16S rRNA to be 100%; however, they stated that it was not reliable, since the NPV of the technique was determined to be 46% (Lu et al., 1999). Furthermore, the PPV and NPV of the PCR of ureC (glmM) gene was determined to be 100% and 96% and this test was reported as the PCR test with the highest specificity and sensitivity (Lu et al., 1999).

Among the biopsy-based tests in the present study, the best result was obtained by PCR, following histopathology. No significant difference was determined between the gold standard tests and PCR in terms of the rate of *H. pylori* positivity ( $p=0.07$ ). In addition to the fact that 23S rRNA was targeted, performing nested PCR may have increased the sensitivity and specificity. In the studies determining *H. pylori* DNA using PCR, false negative results may also be obtained (Weiss et al., 1994). In our study, 13 false negative results were determined by PCR. False negative results detected by PCR in the present study was considered to be resulted from the patchy localization of the bacteria in stomach and interaction of sample with inhibitors as the PCR method used was conventional.

Serological methods are mostly used in population-based seroprevalence studies, as these tests do not allow the diagnosis of active infections (Göral et al., 2006; Akin et al., 2004). In the populations with high seroprevalence rates, however, serological methods have been suggested to be used as the first method if urea breath test and fecal antigen test are not available (Ozden, 2006). Regarding the high virulence of strains, the presence of anti-CagA antibodies is correlated with CagPAI gene detected by molecular studies.

In the present study, the sensitivity, specificity, PPV and NPV of the ELISA method used to detect anti-*H. pylori* IgG was determined to be 86.2%, 40%, 94.3% and 20%, respectively. As specificity and NPV of this method were determined as low as 40% and 20%, respectively, we considered that it is not a test to be preferred for diagnostic purposes; it can be used as a noninvasive test when urea breath test is not available. In the study by Li et al. the sensitivity and specificity of ELISA method used for the determination of serum IgG positivity was determined to be 97% and 94%; these values were higher than those

determined in our study (Li et al., 1996). In the study by Vinette et al. (2004) in which *H. pylori* was investigated in gastric biopsy samples of 101 pediatric patients, the sensitivity and specificity of serology was found to be 69.2% and 78.2%, respectively. They indicated that this may have been depended on inadequate antibody response at pediatric age group and that the use of serological methods for diagnosis of *H. pylori* is not suitable in pediatric patients (Vinette et al., 2004).

In our study, anti-CagA IgG positivity was determined in 75 patients of 107 patients in whom anti-*H. pylori* IgG positivity was determined; a positivity rate of 70% was calculated for all patients. This rate found in the present study was in parallel to the rates reported in other studies conducted in Turkey (Ozden et al., 2004; Saribasak et al., 2004). Ryan et al., (2001) investigated clarithromycin resistance and virulence genes in gastric biopsy samples of 50 patients by PCR and determined that all *H. pylori* positive strains were VacA-positive and 76% of *H. pylori* positive strains were CagA-positive (1).

Urea breath test is accepted as the most suitable method to diagnose *H. pylori* and for the control of eradication in adult patients with dyspeptic complaints, since urea breath test is easy to use, provides results in short period of time (like 20-30 minutes), and has a quite high sensitivity (Ozden, 2006; Dunn et al., 1997). This method which has the highest sensitivity among noninvasive tests is also used in seroprevalence studies (Dunn et al., 1997; Malaty et al., 2002).

*H. pylori* positivity was determined in 119 patients and *H. pylori* negativity was determined in seven patients by urea breath test in the present study. As compared to the gold standard methods, seven false positive results and four false negative results were obtained. False positive results may be observed as urea breath test is a test based on urease. In our study, the urea breath test was the test with the highest sensitivity (96.5%) among all tests. In the study performed by Lu et al., (2005) on 60 patients who had experienced peptic ulcer hemorrhage, the sensitivity and specificity of urea breath test was reported to be 94% and 85%, respectively. Vaira and Vakil investigated the noninvasive methods and determined the specificity and sensitivity of urea breath test to be 94.7% and 95.7%, respectively. Moreover, in that particular study, the researchers reported that urea breath test had the highest sensitivity and specificity among noninvasive tests and was a suitable method to be used for diagnosis and treatment control (Hegedus et al., 2002). The sensitivity of the urea breath test in our study was similar to that in other studies; however, its specificity was determined to be lower than that in similar studies due to its high false positivity. Urea breath test was considered to be a reliable noninvasive test for the diagnosis and the control of eradication of *H. pylori* but verification test should be performed for suspicious situations.

While the sensitivity of culture method was found to be 68.1% in determining *H. pylori*, the sensitivities of other five methods was found between 85% and 95%. While the specificities were calculated to be 100% for both culture and histopathological examination methods, the specificities of two invasive methods, PCR and rapid

urease test, was determined to be 70%. Among invasive methods, the specificities of ELISA and urea breath test were observed to be low in our study. PPV of all tests was determined to be higher than 94%; the histopathological examination was found to have the highest NPV.

The results of our study showed that the diagnostic value of invasive methods was higher than that of noninvasive methods.

Urea breath test is the most convenient test in the routine practice for scanning and control after medical treatment. The stool antigen tests become an alternative to urea breath test especially in children with increased use.

As the serologic tests are not a proof of active infection, they are ideal for seroprevalence studies.

In the present study, no significant difference was found between PCR method and gold standard in terms of the rate of *H. pylori* positivity. The use of primers targeting 23S rRNA and the use of nested PCR method in our study increased the specificity of PCR. The determination of *H. pylori* by PCR is on the way to become one of the routine diagnostic methods.

## References

- Akin L, Tezcan S, Haşçelik G, Çakır B, (2004). Seroprevalence and some correlates of Helicobacter pylori at adult ages in Gülveren health district, Ankara, Turkey. *Epidemiol Infect*, **132**, 847-56.
- Asaka M (2002). Helicobacter pylori infection and Gastric Cancer. *Intern Med*, **41**, 1-6.
- Baglan PH, Bozdayı G, Ozkan M, et al (2006). Clarithromycin resistance prevalence and icca gene status in Helicobacter pylori clinical isolates in Turkish patients with duodenal ulcer and functional dyspepsia. *The J Microbiol*, **4**, 409-16.
- Baglan PH, Bozdayı G, Özkan M, Özden A (2005). Comparison of the E-Test and the Agar dilution method to detect clarithromycin resistant Helicobacter pylori. *Akademik Gastroenteroloji Dergisi*, **4**, 83-7.
- Brandi G, Biavati B, Calabrese C, et al (2006). Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. *Am J Gastroenterol*, **101**, 1756-61.
- Brown LM (2000). Helicobacter pylori: Epidemiology and routes of transmission. *Epidemiol Rev*, **22**, 283-97.
- Bulut Y, Agacayak A, Keles E, Seyrek A, Toraman ZA (2006). The comparison of different primer pairs for the detection of Helicobacter pylori DNA in adenoid and tonsil tissues by PCR. *F.Ü. Sağlık Bil Dergisi*, **20**, 139-42.
- Dunn BE, Cohen H, Blaser MJ (1997). Helicobacter pylori. *Clin Microbiol Rev*, **10**, 720-41.
- Ellidokuz E, Uslan İ, Soytürk M, et al (2003). Is "test & treat" strategy for Helicobacter pylori completely acceptable for developing countries? *Med J Kocatepe*, **1**, 52-6.
- Göral V, Özdal B, Kaplan A, Şit D, Daniş R, (2006). The prevalence of Helicobacter pylori in the Diyarbakır city. *Akademik gastroenteroloji dergisi*, **5**, 47-50.
- Hegedus O, Rydén J, Rehnberg AS, Nilsson S, Hellström PM, (2002). Validated accuracy of a novel urea breath test for rapid Helicobacter pylori detection and in-office analysis. *Eur J Gastroenterol Hepatol*, **14**, 513-20.
- Kaya AD, Öztürk CE, Akcan Y, et al (2007). Prevalence of Helicobacter pylori in symptomatic patients and detection of clarithromycin resistance using melting curve analysis. *Curr Ther Res*, **68**, 151-60.
- Kobayashi D, Eishi Y, Ohkusa T, et al (2002). Gastric mucosal density of Helicobacter pylori estimated by real-time PCR compared with results of urea breath test and histological grading. *J Med Microbiol*, **51**, 305-11.
- Konturek JW (2003). Discovery by Jaworski of Helicobacter pylori and its pathogenetic role in peptic ulcer, gastritis and gastric cancer. *Physiol Pharmacol*, **54**, 23-41.
- Laheij RJ, de Boer WA, Jansen JB, et al (2000). Diagnostic performance of biopsy-based methods for determination of Helicobacter pylori infection without a reference standard. *J Clin Epidemiol*, **53**, 742-6.
- Li C, Ha T, Ferguson DA, et al (1996). A newly developed PCR assay of *H. pylori* in gastric biopsy, saliva, and feces. Evidence of high prevalence of *H. pylori* in saliva supports oral transmission. *Dig Dis Sci*, **41**, 2142-9.
- Lu H, Hsu PI, Graham DY, Yamaoka Y (2005). Duodenal ulcer promoting gene of Helicobacter pylori. *Gastroenterology*, **128**, 833-48.
- Lu JJ, Perng CL, Shyu RY, et al (1999). Comparison of five PCR methods for detection of Helicobacter pylori DNA in gastric tissues. *J Clin Microbiol*, **37**, 772-4.
- Malaty HM, Haveman T, Graham DY, Fraley JK, (2002). Helicobacter pylori infection in asymptomatic children: impact of epidemiologic factors on accuracy of diagnostic tests. *J Pediatr Gastroenterol Nutr*, **35**, 59-63.
- Marshall BJ, Warren JR (1984). Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. *Lancet*, **16**, 1311-5.
- Matsumura M, Hikiba Y, Ogura K, et al (2001). Rapid detection of mutations in the 23S rRNA gene of Helicobacter pylori that confers resistance to clarithromycin treatment to the bacterium. *J Clin Microbiol*, **39**, 691-5.
- Mitchell H, Megraud F (2002). Epidemiology and diagnosis of Helicobacter pylori infection. *Helicobacter*, **7**, 8-16.
- Ogata SK, Kawakami E, Patricio FR, Pedroso MZ, Santos AM, (2001). Evaluation of invasive and non-invasive methods for the diagnosis of Helicobacter pylori infection in symptomatic children and adolescents. *Sao Paulo Med J*, **119**, 67-71.
- Ozden A (2006). Helicobacter Pylori 2006 "WGO-OMGE practice guideline" and "Maastricht III Florence Consensus Report 2005". *Güncel Gastroenteroloji*, **10**, 287-91.
- Ozden A, Bozdayı G, Özkan M, Köse KS (2004). Changes in the seroepidemiological pattern of Helicobacter pylori infection over the last 10 years. *Turk J Gastroenterol*, **15**, 156-8.
- Ryan KA, van Doorn LJ, Moran AP, et al (2001). Evaluation of clarithromycin resistance and cagA and vacA genotyping of Helicobacter pylori strains from the west of Ireland using line probe assays. *J Clin Microbiol*, **39**, 978-80.
- Sanders CJ, Yu Y, Moore DA, Williams IR, Gewirtz AT (2006). Humoral immune response to flagellin requires T Cells and activation of innate immunity. *J Immunol*, **177**, 2810-8.
- Saribasak H, Salih BA, Yamaoka Y, Sander E (2004). Analysis of Helicobacter pylori genotypes and correlation with clinical outcome in Turkey. *J Clin Microbiol*, **42**, 1648-51.
- She FF, Su DH, Lin JY, Zhou LY (2001). Virulence and potential pathogenicity of coccoid Helicobacter pylori induced by antibiotics. *World J Gastroenterol*, **7**, 254-8.
- Somily AM, Morshed MG (2015). Review, An update of laboratory diagnosis of Helicobacter pylori in the Kingdom of Saudi Arabia. *J Infect Dev Ctries*, **9**, 806-14.
- Thamer M, Ray NF, Henderson SC, et al (1998). Influence of the NIH consensus conference on Helicobacter pylori on physician prescribing among a medicaid population. *Med Care*, **36**, 646-60.
- Trebesius K, Panthel K, Strobel S, et al (2000). Rapid and specific detection of Helicobacter pylori macrolide resistance in gastric tissue by fluorescent in situ hybridisation. *Gut*, **46**, 608-14.
- Uyanık MH, Aktaş O, Özbek A, Yılmaz Ö, Ayyıldız A (2007).

- Identification of *Helicobacter pylori*: comparison of methods. *Turk J Infect*, **21**, 123-8.
- Vinette KM, Gibney KM, Proujansky R, Fawcett PT (2004). Comparison of PCR and clinical laboratory tests for diagnosing *H. pylori* infection in pediatric patients. *BMC Microbiol*, **4**, 5-12.
- Weiss J, Mecca J, da Silva E, Gassner D (1994). Comparison of PCR and other diagnostic techniques for detection of *Helicobacter pylori* infection in dyspeptic patients. *J Clin Microbiol*, **32**, 1663-8.
- Wong A, Ching SS, Long AS (2014). The use of a second biopsy from the gastric body for the detection of *Helicobacter pylori* using rapid urease test. *Singapore Med J*, **55**, 644-7.
- World Health Organization International (1997). Agency for Research on Cancer, Monographs on the Evaluation of Carcinogenic Risks to Humans Infection with *Helicobacter Pylori* (Group 1). 61, 177.
- Yang KC, Chu A, Liao CS, Lin YM, Wang GM (2006). Evaluation of the role of *H. pylori* infection in pathogenesis of gastric cancer by immunoblot assay. *World J Gastroenterol*, **12**, 7029-32.